Skip to main content

Table 3 Immunological Assays

From: Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

  Biomaterial
Assay PBMC1 PB Immune cells2 CSF2
Flow cytometric assessment of CD49d and CD62L expression X   
In vitro transmigration across BBB X   
VZV-specific T-cell response X   
Immune phenotyping via flow cytometry X X X
  1. 1purified via density gradient centrifugation and cryo-preserved
  2. 2freshly obtained, treated with erythrocyte-lysis buffer